drugset
drugset / Trial / NCT05069714

One or Two Week Methotrexate Discontinuation on Efficacy of Influenza Vaccination in Rheumatoid Arthritis.

NCT05069714 ↗

Phase 3 Completed 184 enrolled Seoul National University Hospital
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a multi-center, randomized, single-blinded, prospective, parallel group intervention study to investigate whether methotrexate (MTX) discontinuation for 1 week is non-inferior to MTX discontinuation for 2 weeks in regard to satisfactory vaccination response to a seasonal influenza.

Timeline

Start
2021-10-01
Primary completion
2022-09-30
Completion
2022-09-30

Outcome

Met primary endpoint

paper CONCLUSION: A temporary discontinuation of MTX for 1 week after vaccination was noninferior to a discontinuation of MTX for 2 weeks after vaccination PMID 35930728 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Methotrexate Small molecule — —

Indications

influenza rheumatoid arthritis